Manufacturing businesses often invest in new equipment to improve capacity, efficiency or production quality. However, the purchase price of machinery is only one part of the decision. Financing costs, installation, supporting systems and future operating expenses can influence the actual cost of an expansion.

Before taking on additional debt, businesses should understand how borrowing will affect cash flow over the repayment period. MSMEs undertaking eligible projects can also examine reducing finance costs during capacity expansion when evaluating the economics of a proposed investment.

This becomes particularly important when several machines or facility improvements are being implemented together. A project-level assessment can provide a better picture than evaluating every purchase separately.

Pharmaceutical manufacturers may also undertake capital expenditure to strengthen production and quality systems. Depending on the facility, improvements can extend to manufacturing equipment, controlled production areas, utilities and testing capabilities.

In this situation, businesses can consider building a compliant pharmaceutical manufacturing setup while reviewing the role that RPTUAS could play in their modernisation plans. The purpose and supporting evidence for individual expenditure should be established before treating it as potentially eligible.

Manufacturers can make this assessment more structured by maintaining quotations, equipment specifications, financing details and records explaining why each investment is required.

Ultimately, a capital project should make commercial and operational sense independently. Relevant schemes can then be evaluated as an additional factor that may improve the financial feasibility of an otherwise necessary investment.